Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial.

Published in:

Diabetic Medicine, 2015, v. 32, n. 4, p. 531, doi. 10.1111/dme.12624

By:

• Bailey, C. J.;
• Morales Villegas, E. C.;
• Woo, V.;
• Tang, W.;
• Ptaszynska, A.;
• List, J. F.

Publication type:

Article